These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 18375641)

  • 21. A case of severe hyperammonemia and unconsciousness following sodium valproate intoxication.
    Lee WL; Yang CC; Deng JF; Chen YF; Lin HD; Wang PH
    Vet Hum Toxicol; 1998 Dec; 40(6):346-8. PubMed ID: 9830696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L-Arginine in the treatment of valproate overdose - five clinical cases.
    Schrettl V; Felgenhauer N; Rabe C; Fernando M; Eyer F
    Clin Toxicol (Phila); 2017 Apr; 55(4):260-266. PubMed ID: 28152637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valproate-induced hyperammonemic encephalopathy, rapidly improved by i.v. carnitine and glucose/thiamine.
    Bøhmer T; Bøen A; Høymork SC
    Scand J Gastroenterol; 2010 Jun; 45(6):762-3. PubMed ID: 20163200
    [No Abstract]   [Full Text] [Related]  

  • 24. Extracorporeal elimination in acute valproic acid poisoning.
    Thanacoody RH
    Clin Toxicol (Phila); 2009 Aug; 47(7):609-16. PubMed ID: 19656009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe acute hyperammonemia after brief exposure to valproate.
    Eubanks AL; Aguirre B; Bourgeois JA
    Psychosomatics; 2008; 49(1):82-3. PubMed ID: 18212182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valproic Acid Overdose: Case Report and Literature Review.
    Patel J; Berezowski I; Mazer-Amirshahi M; Frasure SE; Tran QK; Pourmand A
    J Emerg Med; 2022 Nov; 63(5):651-655. PubMed ID: 36229318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valproate-induced hyperammonemic encephalopathy.
    Segura-Bruna N; Rodriguez-Campello A; Puente V; Roquer J
    Acta Neurol Scand; 2006 Jul; 114(1):1-7. PubMed ID: 16774619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Valproate-associated hyperammonemic encephalopathy.
    Wadzinski J; Franks R; Roane D; Bayard M
    J Am Board Fam Med; 2007; 20(5):499-502. PubMed ID: 17823470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe valproic acid intoxication is associated with atrial tachycardia: secondary detoxication by hemoperfusion.
    Meyer S; Kuhlmann MK; Peters FT; Limbach HG; Lindinger A
    Klin Padiatr; 2005; 217(2):82-5. PubMed ID: 15770579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The consequences of valproate overdose.
    Davison AS; Milan AM; Roberts NB
    Clin Chem; 2011 Sep; 57(9):1233-7. PubMed ID: 21873573
    [No Abstract]   [Full Text] [Related]  

  • 31. Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman.
    Mallet L; Babin S; Morais JA
    Ann Pharmacother; 2004 Oct; 38(10):1643-7. PubMed ID: 15316109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valproate-induced hyperammonemic encephalopathy treated by hemodialysis.
    Tsai MF; Chen CY
    Ren Fail; 2008; 30(8):822-4. PubMed ID: 18791959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report.
    Maldonado C; Guevara N; Silveira A; Fagiolino P; Vázquez M
    J Int Med Res; 2017 Jun; 45(3):1268-1272. PubMed ID: 28425821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation.
    Schiavo A; Maldonado C; Vázquez M; Fagiolino P; Trocóniz IF; Ibarra M
    Eur J Pharm Sci; 2023 Apr; 183():106399. PubMed ID: 36740101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute valproic acid overdose: enhance elimination with multiple-doses activated charcoal.
    Vannaprasaht S; Tiamkao S; Sirivongs D; Piyavhatkul N
    J Med Assoc Thai; 2009 Aug; 92(8):1113-5. PubMed ID: 19694338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Acute valproic acid intoxication: interest of a treatment by extracoporeal elimination combined with L-carnitine].
    Alluin A; Jezequel J; Gauthier N; Desmaretz JL; Canevet C
    Ann Fr Anesth Reanim; 2011 Oct; 30(10):752-4. PubMed ID: 21782376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Valproate-associated hyperammonemic encephalopathy. Report of one case].
    Young P; Finn BC; Alvarez F; Bruetman JE; Trimarchi H
    Rev Med Chil; 2007 Nov; 135(11):1446-9. PubMed ID: 18259656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
    Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H
    Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management.
    Chopra A; Kolla BP; Mansukhani MP; Netzel P; Frye MA
    Gen Hosp Psychiatry; 2012; 34(3):290-8. PubMed ID: 22305367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different clinical manifestations of hyperammonemic encephalopathy.
    Gomceli YB; Kutlu G; Cavdar L; Sanivar F; Inan LE
    Epilepsy Behav; 2007 Jun; 10(4):583-7. PubMed ID: 17412645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.